Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells

Oncogene volume 25, pages 3719–3734 (2006)Cite this article

Abstract

Hormones acting through G protein-coupled receptors (GPCRs) can cause androgen-independent activation of androgen receptor (AR) in prostate cancer cells. Regulators of G-protein signaling (RGS) proteins, through their GTPase activating protein (GAP) activities, inhibit GPCR-mediated signaling by inactivating G proteins. Here, we identified RGS2 as a gene specifically downregulated in androgen-independent prostate cancer cells. Expression of RGS2, but not other RGS proteins, abolished androgen-independent AR activity in androgen-independent LNCaP cells and CWR22Rv1 cells. In LNCaP cells, RGS2 inhibited Gq-coupled GPCR signaling. Expression of exogenous wild-type RGS2, but not its GAP-deficient mutant, significantly reduced AR activation by constitutively activated GqQ209L mutant whereas silencing endogenous RGS2 by siRNA enhanced GqQ209L-stimulated AR activity. RGS2 had no effect on RGS-insensitive GqQ209L/G188S-induced AR activation. Furthermore, extracellular signal-regulated kinase 1/2 (ERK1/2) was found to be involved in RGS2-mediated regulation of androgen-independent AR activity. In addition, RGS2 functioned as a growth suppressor for androgen-independent LNCaP cells whereas androgen-sensitive LNCaP cells with RGS2 silencing had a growth advantage under steroid-reduced conditions. Finally, RGS2 expression level was significantly decreased in human prostate tumor specimens. Taken together, our results suggest RGS2 as a novel regulator of AR signaling and its repression may be an important step during prostate tumorigenesis and progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Abrahamsson PA . (1999). Endocr Relat Cancer 6: 503–519.

  • Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ . (2003). Cancer Res 63: 1981–1989.

  • Ben-Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP et al. (1999). J Urol 161: 970–976.

  • Berman DM, Wilkie TM, Gilman AG . (1996). Cell 86: 445–452.

  • Burchett SA, Bannon MJ, Granneman JG . (1999). J Neurochem 72: 1529–1533.

  • Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, Levesque J et al. (2000). Prostate 45: 19–35.

  • Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA et al. (2002). Urology 60: 760–765.

  • Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C . (1992). J Urol 147: 798–803.

  • Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA . (2005). Nature 436: 272–276.

  • Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ et al. (1996). Cancer Res 56: 4475–4482.

  • Daaka Y . (2004). Sci STKE 216: 2–20.

  • Dai J, Shen R, Sumitomo M, Stahl R, Navarro D, Gershengorn MC et al. (2002). Clin Cancer Res 8: 2399–2405.

  • Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D et al. (2003). Prostate 54: 249–257.

  • DiBello PR, Garrison TR, Apanovitch DM, Hoffman G, Shuey DJ, Mason K et al. (1998). J Biol Chem 273: 5780–5784.

  • Druey KM, Blumer KJ, Kang VH, Kehrl JH . (1996). Nature 379: 742–746.

  • Feldman BJ, Feldman D . (2001). Nat Rev Cancer 1: 34–45.

  • Frost JA, Geppert TD, Cobb MH, Feramisco JR . (1994). Proc Natl Acad Sci USA 91: 3844–3848.

  • Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ . (1999). Cancer Res 59: 279–284.

  • Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M . (2001). J Urol 165: 1033–1036.

  • Grillet N, Dubreuil V, Dufour HD, Brunet JF . (2003). J Neurosci 23: 10613–10621.

  • Grossmann ME, Huang H, Tindall DJ . (2001). J Natl Cancer Inst 93: 1687–1697.

  • Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF et al. (2001). Blood 98: 1429–1439.

  • Gutkind JS . (2000). Sci STKE 40: RE1.

  • Gutowski S, Smrcka A, Nowak L, Wu DG, Simon M, Sternweis PC . (1991). J Biol Chem 266: 20519–20524.

  • Hains MD, Siderovski DP, Harden TK . (2004). Methods Enzymol 389: 71–88.

  • Heinlein CA, Chang C . (2004). Endocr Rev 25: 276–308.

  • Hepler JR, Berman DM, Gilman AG, Kozasa T . (1997). Proc Natl Acad Sci USA 94: 428–432.

  • Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N et al. (2003). J Clin Invest 111: 445–452.

  • Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A . (1996). Prostate 28: 129–135.

  • Hollinger S, Hepler JR . (2002). Pharmacol Rev 54: 527–559.

  • Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF . (2002). Prostate 50: 222–235.

  • Ingi T, Krumins AM, Chidiac P, Brothers GM, Chung S, Snow BE et al. (1998). J Neurosci 18: 7178–7188.

  • Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M et al. (2003). Nat Biotechnol 21: 635–637.

  • Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. (2005). CA Cancer J Clin 55: 10–30.

  • Kammermeier PJ, Ikeda SR . (1999). Neuron 22: 819–829.

  • Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK . (2002). Carcinogenesis 23: 967–975.

  • Karan D, Schmied BM, Dave BJ, Wittel UA, Lin MF, Batra SK . (2001). Clin Cancer Res 7: 3472–3480.

  • Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P et al. (2005). J Biol Chem 280: 11583–11589.

  • Kehrl JH, Sinnarajah S . (2002). Int J Biochem Cell Biol 34: 432–438.

  • Lee LF, Guan J, Qiu Y, Kung HJ . (2001). MolCell Biol 21: 8385–8397.

  • Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF . (2003). Oncogene 22: 781–796.

  • Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G et al. (2002). Cancer Res 62: 6039–6044.

  • Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY et al. (2003). J Biol Chem 278: 50902–50907.

  • Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF . (1998). J Biol Chem 273: 5939–5947.

  • Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS et al. (1996). Cancer Res 56: 663–668.

  • Neubig RR, Siderovski DP . (2002). Nat Rev Drug Discov 1: 187–197.

  • Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, Bai D, Houston FP, Whishaw IQ et al. (2000). Proc Natl Acad Sci USA 97: 12272–12277.

  • Porter AT, Ben-Josef E . (2001). Urol Oncol 6: 131–138.

  • Posner BA, Mukhopadhyay S, Tesmer JJ, Gilman AG, Ross EM . (1999). Biochemistry 38: 7773–7779.

  • Robinet EA, Wurch T, Pauwels PJ . (2001). Neuroreport 12: 1731–1735.

  • Ross EM, Wilkie TM . (2000). Annu Rev Biochem 69: 795–827.

  • Roy AA, Lemberg KE, Chidiac P . (2003). Mol Pharmacol 64: 587–593.

  • Sadi MV, Walsh PC, Barrack ER . (1991). Cancer 67: 3057–3064.

  • Salim S, Sinnarajah S, Kehrl JH, Dessauer CW . (2003). J Biol Chem 278: 15842–15849.

  • Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S et al. (1997). J Biol Chem 272: 17485–17494.

  • Schmitt JM, Stork PJ . (2000). J Biol Chem 275: 25342–25350.

  • Schwable J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, Steur C et al. (2005). Blood 105: 2107–2114.

  • Shah GV, Rayford W, Noble MJ, Austenfeld M, Weigel J, Vamos S et al. (1994). Endocrinology 134: 596–602.

  • Siderovski DP, Heximer SP, Forsdyke DR . (1994). DNA Cell Biol 13: 125–147.

  • Sinnarajah S, Dessauer CW, Srikumar D, Chen J, Yuen J, Yilma S et al. (2001). Nature 409: 1051–1055.

  • Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS et al. (1999). In vitro Cell Dev Biol Anim 35: 403–409.

  • Tang KM, Wang GR, Lu P, Karas RH, Aronovitz M, Heximer SP et al. (2003). Nat Med 9: 1506–1512.

  • Taplin ME, Balk SP . (2004). J Cell Biochem 91: 483–490.

  • Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y . (2003). Cancer Res 63: 2037–2041.

  • Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF et al. (2002). Cancer Res 62: 6606–6614.

  • Thebault S, Roudbaraki M, Sydorenko V, Shuba Y, Lemonnier L, Slomianny C et al. (2003). J Clin Invest 111: 1691–1701.

  • Tovey SC, Willars GB . (2004). Mol Pharmacol 66: 1453–1464.

  • Tu Y, Woodson J, Ross EM . (2001). J Biol Chem 276: 20160–20166.

  • Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA et al. (2004). Cancer Res 64: 7156–7168.

  • Wang J, Tu Y, Mukhopadhyay S, Chidiac P, Biddlecome GH, Ross EM . (1998) In: Manning DR (ed). G Proteins: Techniques of Analysis. CRC Press: Boca Raton, pp 123–151.

    Google Scholar 

  • Weng J, Wang J, Cai Y, Stafford LJ, Mitchell D, Ittmann M et al. (2005). Int J Cancer 113: 811–818.

  • Wieland T, Mittmann C . (2003). Pharmacol Ther 97: 95–115.

  • Wilkie TM, Gilbert DJ, Olsen AS, Chen XN, Amatruda TT, Korenberg JR et al. (1992). Nat Genet 1: 85–91.

  • Wu HK, Heng HH, Shi XM, Forsdyke DR, Tsui LC, Mak TW et al. (1995). Leukemia 9: 1291–1298.

  • Xia C, Ma W, Wang F, Hua SB, Liu M . (2001). Oncogene 20: 5903–5907.

  • Xie Y, Gibbs TC, Mukhin YV, Meier KE . (2002). J Biol Chem 277: 32516–32526.

  • Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA et al. (2000). Cancer Res 60: 6568–6572.

  • Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C . (1999). Proc Natl Acad Sci USA 96: 5458–5463.

Download references

Acknowledgements

We thank Dr David Siderovski, University of North Carolina at Chapel Hill for providing anti-RGS2 antibody, Dr Paul C Sternweis (UT Southwestern Medical Center) for the polyclonal rabbit Gq antibody and Dr Melanin Cobb (UT Southwestern Medical Center) for providing dominant-negative MEK1 and ERK2 mutants. We also thank Dr Zafar Nawaz for critical reading of the manuscript. This work was supported in part by NIH Grant number P20 RR018759 from the National Center for Research Resource (YT and MFL), CA88184 (MFL), Creighton Health Future Foundation (YT), Nebraska State LB692 (YT) and National Scientist Development Grant from American Heart Association (YT).

Author information

Author notes

  1. X Cao and J Qin: These authors contributed equally to the work.

Authors and Affiliations

  1. Department of Pharmacology, Creighton University School of Medicine, Omaha, NE, USA

    X Cao, J Qin, Y Xie, O Khan, F Dowd, M Scofield & Y Tu

  2. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA

    M-F Lin

Authors
  1. X Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Dowd
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Scofield
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M-F Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Tu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Tu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cao, X., Qin, J., Xie, Y. et al. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 25, 3719–3734 (2006). https://doi.org/10.1038/sj.onc.1209408

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209408

Keywords

This article is cited by

Search

Advanced search

Quick links